PET联合CT在弥漫大B细胞淋巴瘤(DLBCL)的诊断价值及特征研究

摘要/Abstract

摘要：目的探讨正电子发射计算机断层显像(PET)联合CT应用于诊断DLBCL的价值及特征。方法选取2018年4月—2019年12月作为本次研究区间,选择在此区间内洛阳市中心医院收治的110例疑似DLBCL患者作为本次研究对象,所有患者均接受PET/CT检查,记录其PET/CT检查结果并与最终病理确诊结果对比,计算PET/CT对DLBCL诊断敏感性、特异性。结果 110例疑似DLBCL患者经PET/CT检查对DLBCL检出率为91.82%,病理确诊率为92.73%,P>0.05。PET/CT检查对DLBCL诊断敏感性为98.04%、特异性为87.50%。结论应用PET/CT诊断DLBCL具有较高的临床应用价值。

关键词:弥漫大B细胞淋巴瘤,正电子发射型计算机断层扫描技术,诊断,特征

Abstract:Objective: To explore the value and characteristics of positron emission computed tomography (PET) combined with CT in the diagnosis of DLBCL.Methods: The period from April 2018 to December 2019 was selected as the study interval, and 110 patients with suspected DLBCL admitted to our hospital in this interval were selected as the study objects.All patients received PET/CT examination, their PET /CT results were recorded and compared with the final pathological diagnosis results, and the sensitivity and specificity of PET/CT for DLBCL diagnosis was calculated.Results: In the 110 patients with suspected DLBCL, the detection rate of DLBCL was 91.82% by PET/CT,and the pathological diagnosis rate was 92.73%.Data comparisonP>0.05. The sensitivity of PET/CT to DLBCL diagnosis was 98.04%, and the specificity was 87.50%.Conclusion: The application of PET/CT to diagnose DLBCL has high clinical application value.

Key words:diffuse large B-cell lymphoma,positron emission computed tomography,diagnosis,characteristics

中图分类号:

R445

付立武, 尤斌. PET联合CT在弥漫大B细胞淋巴瘤(DLBCL)的诊断价值及特征研究[J]. betway必威登陆网址（betway.com ）学报, 2021, 42(4): 305-307.

FU Li-wu, YOU Bin. The diagnostic value and characteristics of PET combined with CT in diffuse large B-cell lymphoma (DLBCL)[J]. Journal of Shandong First Medical Unversity & Shandong Academy of Medical Sciences, 2021, 42(4): 305-307.

参考文献

[1] Mikhaeel NG, Smith D, Dunn JT, et al. Combination of baseline metabolic tumour volume and early response on PET/CT improves progression-free survival prediction in DLBCL[J].Eur J Nucl Med Mol Imaging, 2016, 43(7): 1209-1219.
[2] 杨新蕊,姜玲,程玉卉,等.前纵隔弥漫性大B淋巴瘤与侵袭性胸腺瘤的鉴别诊断[J].泰山医学院学报,2019,40(6):426-429.
[3] 鸿良,刘婷,马超,等.原发中枢神经系统淋巴瘤20例临床特点与预后分析[J].中国实验血液学杂志,2015;23(1):111-118.
[4] 秦国祥. 脾多肽注射液联合R-CHOP方案治疗弥漫大B细胞淋巴瘤的近中期疗效[J].中国实用医刊,2020,47(8):96-100.
[5] 黄春晖,孙守金,谢凤玲. CHOP-14与CHOP-21治疗弥漫性大B细胞淋巴瘤的疗效观察[J]. 临床医学,2009,29(2):83-84.
[6] 杨燕,朱海燕,于力.¹⁸F-F DG PET /CT对弥漫性大B细胞淋巴瘤的预后评估意义研究进展[J]. 中国实验血液学杂志,2015,23 (1) : 255-260.
[7] 应志涛,王雪鹃,宋玉琴,等.弥漫大B细胞淋巴瘤患者规范治疗后行¹⁸F-FDG PET／CT检查的预后意义[J].中华血液学杂志,2012,33(10):810-813.
[8] 胡娜, 吴永港, 肖立志, 等.¹⁸F-FDG PET/CT 代谢活性参数及其在淋巴瘤中的应用[J]. 国际放射医学核医学杂志, 2015,39(4): 342-347.
[9] 梁颖, 吴宁, 方艳, 等.¹⁸F-FDG PET/CT 显像 SUVmax、 MTV和 TLG 判断弥漫性大 B 细胞淋巴瘤的预后价值[J].中华核医学与分子影像杂志, 2015, 35(2): 97-101.
[10] 吴敏,赵红光,关锋,等.¹⁸F-FDG PET／CT显像在原发性中枢神经系统淋巴瘤诊断中的应用[J].吉林大学学报(医学版),2015,41(2):401-404.
[11] 张云.¹⁸F-FDGPET/CT 在弥漫大 B 细胞淋巴瘤化疗中期诊断及疗效评价的意义[J]. 新疆医学,2015,08(10):1401-1403.
[12] 丁重阳,刘红宇,李天女,等. 化疗后 PET/CT 在弥漫大 B 细胞淋巴瘤疗效评价中的价值[J]. 中国实验血液学杂志,2015,05(4):1013-1016.
[13] 范洋,张玥伟,杨志等 . 化疗早期¹⁸F-FDGPET／CT 评价弥漫性大 B 细胞淋巴瘤的疗效及预后预测[J].肿瘤,2015,35(9):1013-1020.
[14] 沈小东,王喜,钱申贤 .¹⁸F-氟代脱氧葡萄糖 PET/CT 显像评估弥漫大 B 细胞淋巴瘤及联合自体高效 CIK 细胞化疗治疗的效果研究[J].中国现代医生,2016,54(17):13-16.
[15] 杨烨,李肖红. 弥漫大B细胞淋巴瘤在化疗中期行¹⁸F-FDGPET／CT 的临床应用价值[J].新疆医科大学学报,2014,37(5):574-577.
[16] 胡娜, 吴永港, 肖立志, 等.¹⁸F-FDG PET/CT 代谢活性参数及其在淋巴瘤中的应用[J].国际放射医学核医学杂志,2015,39(4):342-347.
[17] 梁颖, 吴宁, 方艳, 等.¹⁸F-FDG PET/CT 显像 SUVmax、 MTV和 TLG 判断弥漫性大 B 细胞淋巴瘤的预后价值[J].中华核医学与分子影像杂志,2015,35(2):97-101.
[18] 张玥伟, 范洋, 杨志, 等. 化疗早期及中期¹⁸F-FDG PET/CT 显像对 56 例弥漫大 B 细胞淋巴瘤患者预后的评估价值[J].中华血液学杂志,2015,36(10):824-829.
[19] 丁重阳, 郭喆, 吴宇霖, 等.¹⁸F-FDG PET/CT 在局限期小细胞肺癌预后评估中的价值[J].中华核医学与分子影像杂志,2017,37(11):694-699.
[20] 尹亮,林志春,岳建兰,等.原发性中枢神经系统淋巴瘤PET／CT影像表现[J].中国实验血液学杂志,2016,24(5):1416-1420.